Low-dose intravenous cyclophosphamide in systemic sclerosis: An open prospective efficacy study in patients with early diffuse disease

Scandinavian Journal of Rheumatology

Volumn 35, Issue 1, 2006, Pages 35-38

  Valentini, G ^a   Paone, C ^a   La Montagna, G ^a   Chiarolanza, I ^a   Menegozzo, M ^a   Colutta, E ^a   Ruocco, L ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFECTIVE AGENT; ANTITHROMBOCYTIC AGENT; CYCLOPHOSPHAMIDE; DOMPERIDONE; MESNA; NIFEDIPINE; OMEPRAZOLE; ONDANSETRON; PREDNISONE; STEROID;

ADULT; ARTICLE; BLADDER INJURY; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CAPACITY; MALE; NAUSEA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; SYSTEMIC SCLEROSIS; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT INJURY;

ADULT; ANTIRHEUMATIC AGENTS; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PATIENT SELECTION; PREDNISONE; SCLERODERMA, DIFFUSE; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 32644482924     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740510026896     Document Type: Article

References (17)

1. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993;20:838-44.
2. Akesson A, Scheja A, Lundin A, Wollheim FA. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994;37:729-35.
3. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-54.
4. Pakas I, Ioannidis JPA, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002;29:298-304.
5. Airo P, Danieli E, Parrinello G, Antonioli CM, Cavazzana I, Toniati P, et al. Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheum 2004;22:573-8.
6. Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk MA, Haznedarglu IC, et al. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 2003;48:2256-61.
7. Martin-Suarez I, D'Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GRV. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997;56:481-7.
8. D'Angelo S, Cuomo G, Paone C, Collutta E, La Montagna G, Valentini G. Low-dose intravenous cyclophosphamide in systemic sclerosis: a preliminary safety study. Clin Rheumatol 2003;22:393-6.
9. LeRoy EC, Black C, Fleiscmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
10. Valentini G, Medsger TA Jr, Silman AJ, Bombardieri S. The assessment of the patient with systemic sclerosis. Clin Exp Rheumatol 2003;21(Suppl 29):S1-56.
11. Ogilvie CM, Forster RE, Blakemore WS, Morton JW. A standardized breath holding technique for clinical measurement of the diffusing capacity of the lung for carbon monoxide. J Clin Invest 1957;36:1-17.
12. American Thoracic Society Standardization of Spirometry, 1994 update. Am J Respir Crit Care Med 1995;152:1107-36.
13. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
14. Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991;4:27-31.
15. Medsger TA, Silman AJ, Steen VD, Black CM, Akesson A, Bacon P, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.
16. Bazzichi L, Rossi A, De Giorgio F, Gesi M, Lenzi P, Pellegrini A. Clinical improvement in systemic sclerosis resulting from urokinase therapy explained by light and electron microscopy skin examination. Scand J Rheumatol 2003;32:261-7.
17. Sandqvist G, Eklund M, Akesson A, Nordenskiold U. Daily activities and hand function in women with scleroderma. Scand J Rheumatol 2004;33:102-7.